Patent ID: 11884725
Assignee: AMPSOURCE BIOPHARMA SHANGHAI INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 4:
5. The antibody or the antigen-binding fragment thereof according to claim 4, wherein
(1) the antibody or an antigen-binding fragment comprises the following six CDRs defined in accordance with the IMGT numbering system: CDR-H1 as shown by SEQ ID NO: 18, CDR-H2 as shown by SEQ ID NO: 19 and CDR-H3 as shown by SEQ ID NO: 20; CDR-L1 as shown by SEQ ID NO: 27, CDR-L2 as shown by SEQ ID NO: 25 and CDR-L3 as shown by SEQ ID NO: 2; or
(2) the antibody or an antigen-binding fragment comprises the following six CDRs defined in accordance with the Chothia numbering system: CDR-H1 as shown by SEQ ID NO: 16, CDR-H2 as shown by SEQ ID NO: 17 and CDR-H3 as shown by SEQ ID NO: 15; CDR-L1 as shown by SEQ ID NO: 24, CDR-L2 as shown by SEQ ID NO: 25 and CDR-L3 as shown by SEQ ID NO: 26; or
(3) the antibody or an antigen-binding fragment comprises the following six CDRs defined in accordance with the Kabat numbering system:
(3a) CDR-H1 as shown by SEQ ID NO: 13, CDR-H2 as shown by SEQ ID NO: 14 and CDR-H3 as shown by SEQ ID NO: 15; CDR-L1 as shown by SEQ ID NO: 21, CDR-L2 as shown by SEQ ID NO: 22 and CDR-L3 as shown by SEQ ID NO: 23; or
(3b) CDR-H1 as shown by SEQ ID NO: 13, CDR-H2 as shown by SEQ ID NO: 28 and CDR-H3 as shown by SEQ ID NO: 15; CDR-L1 as shown by SEQ ID NO: 29, CDR-L2 as shown by SEQ ID NO: 30 and CDR-L3 as shown by SEQ ID NO: 23.